© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
October 25, 2021
Phase 3 ILLUMINATE showed the percentage of individuals with HIV-1 RNA levels ≥50 copies/mL for the once-a-day combination pill of doravirine/islatravir.
The drug previously received approval to treat mucosal melanoma but could be used in combination with pembrolizumab.
The immune response of all 15 serotypes in the V114 pneumococcal vaccination were higher than those in the PCV13 vaccination.
A study finds that intravenous immunoglobulin therapy is a beneficial way to combat parvovirus-induced PRCA in individuals with anemia.